Zorvolex is a pain relief drug owned by Zyla. The active ingredient in Zorvolex is diclofenac. The drug was first approved for market use on 18 October, 2013 and is available in capsule; oral dosage forms.
As of now, Zorvolex has a total of 7 active patents preventing the production of generic versions of the drug. These patents will expire on 23 April, 2030, after which we can expect the release of Zorvolex generics.
Zorvolex is used in the treatment of pain. The effectiveness of the drug is primarily due to the active ingredient diclofenac, which has potent anti-inflammatory and analgesic properties.
Zorvolex is protected by a total of 7 patents, all expiring on 23 April, 2030. These patents revolve around the formulation of the active ingredient Diclofenac. The expiration of these patents will pave the way for the release of Zorvolex generic variants. Below are the details of the patent: